LifeStance Health (LFST)
Market Price (12/28/2025): $7.135 | Market Cap: $2.8 BilSector: Health Care | Industry: Health Care Facilities
LifeStance Health (LFST)
Market Price (12/28/2025): $7.135Market Cap: $2.8 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% | Weak multi-year price returns2Y Excs Rtn is -52%, 3Y Excs Rtn is -26% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 427x |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Health & Wellness Trends. Themes include Telehealth Platforms, and Mental Health Services. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.5% | |
| Key risksLFST key risks include [1] struggles with clinician retention rates reportedly lower than company claims and [2] numerous lawsuits and allegations over its billing practices. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Health & Wellness Trends. Themes include Telehealth Platforms, and Mental Health Services. |
| Weak multi-year price returns2Y Excs Rtn is -52%, 3Y Excs Rtn is -26% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 427x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.5% |
| Key risksLFST key risks include [1] struggles with clinician retention rates reportedly lower than company claims and [2] numerous lawsuits and allegations over its billing practices. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
LifeStance Health (LFST) experienced a significant stock movement of approximately 30.1% between August 31, 2025, and December 28, 2025, primarily driven by strong third-quarter 2025 financial results and positive market reception.
<br><br>
<b>1. Record-Breaking Q3 2025 Financial Performance:</b> LifeStance Health reported record third-quarter 2025 revenue of $363.8 million, representing a 16% year-over-year increase and surpassing consensus estimates. This robust top-line growth was a key factor in the stock's appreciation.
<br><br>
<b>2. Return to Profitability and Exceeding EPS Expectations:</b> The company achieved a net income of $1.1 million in Q3 2025, marking a significant turnaround from losses in the prior year and previous quarter. LifeStance also reached break-even GAAP EPS for the first time as a public company, outperforming analyst expectations for a loss.
<br><br>
<b>3. Substantial Adjusted EBITDA Growth and Margin Expansion:</b> LifeStance reported a 31% increase in Adjusted EBITDA, reaching $40.2 million. This figure exceeded analyst expectations and represented the highest adjusted EBITDA in the company's history, reflecting improved operational leverage and cost efficiencies.
<br><br>
<b>4. Strong Operational Execution and Clinician Growth:</b> The company demonstrated robust operational performance, with visit volumes increasing by 17% and its clinician base growing by 11%, adding 288 net new clinicians. Enhanced clinician productivity also contributed significantly to these gains.
<br><br>
<b>5. Upward Revision of Full-Year Guidance:</b> Following the strong Q3 results, LifeStance Health raised its full-year Adjusted EBITDA guidance, signaling confidence in sustained demand, continued cost controls, and further margin expansion into 2026. This positive outlook reinforced investor confidence.
Show moreStock Movement Drivers
Fundamental Drivers
The 31.5% change in LFST stock from 9/27/2025 to 12/27/2025 was primarily driven by a 26.7% change in the company's P/S Multiple.| 9272025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.42 | 7.13 | 31.55% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1316.48 | 1367.57 | 3.88% |
| P/S Multiple | 1.59 | 2.02 | 26.71% |
| Shares Outstanding (Mil) | 386.73 | 386.96 | -0.06% |
| Cumulative Contribution | 31.55% |
Market Drivers
9/27/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| LFST | 31.5% | |
| Market (SPY) | 4.3% | 4.9% |
| Sector (XLV) | 15.2% | 18.4% |
Fundamental Drivers
The 38.4% change in LFST stock from 6/28/2025 to 12/27/2025 was primarily driven by a 31.2% change in the company's P/S Multiple.| 6282025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.15 | 7.13 | 38.45% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1283.50 | 1367.57 | 6.55% |
| P/S Multiple | 1.54 | 2.02 | 31.19% |
| Shares Outstanding (Mil) | 383.27 | 386.96 | -0.96% |
| Cumulative Contribution | 38.43% |
Market Drivers
6/28/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| LFST | 38.4% | |
| Market (SPY) | 12.6% | 15.4% |
| Sector (XLV) | 17.0% | 31.3% |
Fundamental Drivers
The -4.8% change in LFST stock from 12/27/2024 to 12/27/2025 was primarily driven by a -14.6% change in the company's P/S Multiple.| 12272024 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.49 | 7.13 | -4.81% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1206.09 | 1367.57 | 13.39% |
| P/S Multiple | 2.36 | 2.02 | -14.59% |
| Shares Outstanding (Mil) | 380.36 | 386.96 | -1.74% |
| Cumulative Contribution | -4.84% |
Market Drivers
12/27/2024 to 12/27/2025| Return | Correlation | |
|---|---|---|
| LFST | -4.8% | |
| Market (SPY) | 17.0% | 24.4% |
| Sector (XLV) | 13.8% | 29.5% |
Fundamental Drivers
The 65.0% change in LFST stock from 12/28/2022 to 12/27/2025 was primarily driven by a 66.7% change in the company's Total Revenues ($ Mil).| 12282022 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 4.32 | 7.13 | 65.05% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 820.18 | 1367.57 | 66.74% |
| P/S Multiple | 1.88 | 2.02 | 7.14% |
| Shares Outstanding (Mil) | 357.52 | 386.96 | -8.24% |
| Cumulative Contribution | 63.93% |
Market Drivers
12/28/2023 to 12/27/2025| Return | Correlation | |
|---|---|---|
| LFST | -9.5% | |
| Market (SPY) | 48.0% | 22.4% |
| Sector (XLV) | 17.9% | 22.7% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LFST Return | - | -57% | -48% | 59% | -6% | -4% | -68% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| LFST Win Rate | - | 29% | 58% | 67% | 50% | 42% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| LFST Max Drawdown | - | -64% | -55% | -11% | -39% | -49% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | LFST | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -85.1% | -25.4% |
| % Gain to Breakeven | 570.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
LifeStance Health's stock fell -85.1% during the 2022 Inflation Shock from a high on 7/7/2021. A -85.1% loss requires a 570.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
- Urgent care for mental health.
- One Medical for mental wellness.
- The LensCrafters of psychiatry and therapy.
AI Analysis | Feedback
- Psychiatry and Medication Management: Provides psychiatric evaluations, diagnoses, and manages medication for a range of mental health conditions.
- Psychotherapy and Counseling: Offers individual, group, and family therapy sessions with licensed therapists and counselors to address mental health challenges.
- Transcranial Magnetic Stimulation (TMS): A non-invasive medical procedure used to stimulate nerve cells in the brain to improve symptoms of depression and other conditions.
AI Analysis | Feedback
LifeStance Health (symbol: LFST) primarily sells its mental health services directly to individuals.
The company serves the following categories of individual customers:
- Individuals seeking outpatient mental health treatment for various conditions: This includes patients experiencing a wide range of mental health issues such as depression, anxiety disorders, bipolar disorder, PTSD, ADHD, eating disorders, and more, who are seeking professional psychiatric and therapeutic care.
- Patients across different age groups: LifeStance Health provides services to children, adolescents, adults, and seniors, tailoring treatments to meet the specific developmental and psychological needs of each age demographic.
- Individuals seeking both in-person and virtual care modalities: The company caters to customers who prefer traditional in-person office visits as well as those who benefit from the flexibility and accessibility of telehealth (virtual) appointments for their mental health needs.
AI Analysis | Feedback
nullAI Analysis | Feedback
David Bourdon, Chief Executive Officer
Dave Bourdon was appointed Chief Executive Officer of LifeStance Health effective March 3, 2025. He joined LifeStance Health in 2022 as Chief Financial Officer. Prior to his time at LifeStance, he served as CFO of Magellan Health, a leader in behavioral health and pharmacy management. Earlier, he held multiple roles at Cigna, including CFO of Cigna's U.S. and international healthcare business units. He began his career with the U.S. Coast Guard.
Ryan McGroarty, Chief Financial Officer
Ryan McGroarty was appointed Chief Financial Officer of LifeStance Health effective March 17, 2025. He brings over 25 years of healthcare experience, including 15 years in CFO roles. Previously, Mr. McGroarty served as CFO of Help at Home. Before that, he held multiple CFO positions at Cigna, most recently as Chief Financial Officer of Government Business.
Kenneth Burdick, Executive Chairman
Kenneth Burdick transitioned to Executive Chairman of LifeStance Health effective March 3, 2025, having previously served as CEO and Chairman since September 2022. His career in healthcare spans over 45 years, with significant executive and leadership roles. He served as Executive Vice President of Markets and Products at Centene Corporation and was CEO of WellCare Health Plans, Inc., which was acquired by Centene. He also held various positions at UnitedHealth Group, including CEO of UnitedHealthcare, and Cigna.
Felicia Gorcyca, Chief People Officer
Felicia Gorcyca joined LifeStance Health as its first Chief People Officer in March 2021. She has over 20 years of experience in human capital. Before LifeStance, she was an operations director at TPG Capital, a private equity firm that invests in LifeStance, where she collaborated with portfolio companies on leadership teams and boards. Her background also includes roles as Chief People Officer for Stack Sports and Global Head of People Operations for Solera Inc. She also worked as a consultant for Spencer Stuart, primarily focusing on healthcare services.
Vaughn Vance, Chief Technology Officer
As Chief Technology Officer at LifeStance Health, Vaughn Vance leads the organization's comprehensive technology strategy. He possesses over 25 years of experience in healthcare technology, specializing in digital transformation initiatives, enabling AI-powered insights, and streamlining digital tools to enhance care delivery.
AI Analysis | Feedback
LifeStance Health (LFST) faces several significant risks to its business operations and financial performance. The most prominent challenges revolve around its workforce, its relationships with payers, and its billing practices.
-
Clinician Recruitment and Retention
LifeStance Health consistently grapples with the critical issue of attracting and retaining qualified mental health clinicians. Despite efforts to expand its clinician base, the company has struggled with retention rates, which have been reported to be lower than company claims. This challenge is exacerbated by a competitive mental health sector and directly impacts LifeStance's capacity to deliver services and achieve growth. Difficulties in maintaining workforce stability can limit operational momentum and growth expectations.
-
Reimbursement and Payer Relationship Challenges
The company's revenue and profitability are significantly influenced by insurance reimbursement models and its relationships with third-party payers. There is a risk of reduced reimbursement rates and potential rate cuts, which can adversely affect revenue per visit and overall financial health. Complex and sometimes challenging relationships with insurance providers, along with evolving regulations around virtual healthcare delivery and a potential shift to value-based care models, present ongoing financial and operational uncertainties for LifeStance Health.
-
Billing Practices and Litigation
LifeStance Health has faced numerous complaints and lawsuits concerning its billing practices. These allegations include overbilling, fraudulent billing, and unfair business practices such as scheduling unrequested appointments to incur cancellation fees, adding unearned billing codes, and charging for services not rendered. Such issues have led to class-action lawsuits, legal settlements, and potential damage to the company's reputation, posing significant financial and operational risks. Additionally, former employees have alleged that payment arrangements sometimes require clinicians to repay salary advances if productivity targets are not met, potentially violating labor laws.
AI Analysis | Feedback
There are two clear emerging threats for LifeStance Health (LFST):
- Rapid Advancement and Adoption of Artificial Intelligence (AI) and Digital Therapeutics (DTx): The proliferation of AI-powered chatbots, virtual assistants, and FDA-approved digital therapeutics is creating alternative, often lower-cost and highly scalable, solutions for mental health support. These technologies can address lower-acuity conditions, provide interim support, or even augment traditional therapy, potentially reducing the demand for or frequency of in-person or telehealth sessions with human providers. This parallels the shift seen when Netflix offered a scalable, convenient alternative to Blockbuster's physical rentals, threatening their core business model.
- Vertical Integration by Health Payers and Large Healthcare Systems: Major health insurance companies and large integrated healthcare systems are increasingly acquiring or building their own mental health provider networks. By integrating mental health services directly into their ecosystem, these entities can steer their beneficiaries towards in-house providers, optimize care coordination with primary and specialty medical care, and leverage their existing patient base and negotiation power. This threatens standalone providers like LifeStance Health by controlling patient flow, potentially limiting access to covered lives, and creating a more closed ecosystem, similar to how YouTube (owned by Google) could leverage its platform and user base to challenge traditional cable content providers.
AI Analysis | Feedback
LifeStance Health (LFST) operates within the U.S. behavioral health market, providing a range of outpatient mental healthcare services. These services include in-person and telehealth options for therapy, psychiatry, psychological testing, and medication management, catering to children, adolescents, and adults.
The addressable market for LifeStance Health's main products and services is the U.S. behavioral health market.
- The U.S. behavioral health market size was valued at approximately $92.2 billion in 2024, and is projected to grow to $151.62 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 5.1% from 2024 to 2034.
- Another estimate indicates the U.S. behavioral health market size was $94.82 billion in 2025 and is anticipated to reach around $165.38 billion by 2034, with a CAGR of 6.40% during the forecast period from 2025 to 2034.
- Additionally, the U.S. behavioral health market was valued at $87.82 billion in 2024 and is projected to grow to $132.46 billion by 2032, at a CAGR of 5.3%.
AI Analysis | Feedback
LifeStance Health (LFST) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Expansion of Clinician Base: LifeStance Health consistently identifies the growth in its network of mental health clinicians as a primary driver for increasing visit volumes and, consequently, revenue. The company added 285 net clinicians in the third quarter of 2024, bringing its total to 7,269, representing a 13% year-over-year growth. This expansion is expected to continue.
- Increased Visit Volumes and Clinician Productivity: Beyond simply adding clinicians, LifeStance focuses on enhancing the productivity of its existing clinician base, leading to higher visit volumes. In Q3 2024, visit volumes increased by 15% year-over-year to 2.0 million, driven by clinician growth and improved productivity. The company expects to maintain elevated productivity levels.
- Improvements in Revenue per Visit (Rate Improvements): LifeStance has seen improvements in its total revenue per visit, which contributes to overall revenue growth. The company anticipates low to mid-single-digit rate improvements as a driver for 2026 revenue growth.
- Strategic Expansion through New Centers and Potential Acquisitions: The company plans to open 20-25 new centers in 2025 as part of its organic expansion strategy. Additionally, LifeStance is considering potential mergers and acquisitions (M&A) opportunities to facilitate market growth, although these are not currently factored into its existing guidance.
- Leveraging Technology and AI Tools: LifeStance Health plans to invest in technology, digital, and AI tools to enhance operational efficiency, automate processes, improve accuracy, and support its clinicians. These advancements are expected to enable more efficient service delivery and facilitate continued margin expansion alongside sustainable growth.
AI Analysis | Feedback
Share Repurchases
- No significant share repurchases by LifeStance Health were identified in the provided period.
Share Issuance
- LifeStance Health completed its Initial Public Offering (IPO) on June 10, 2021, selling 32.8 million shares and raising net proceeds of $558 million.
- In May 2024, a secondary public offering of 20 million shares was priced at $6.25 per share, with all proceeds going to selling stockholders, not the company.
- The number of shares outstanding has generally increased, from approximately 373.65 million in June 2021 to 389.08 million as of June 30, 2025.
Inbound Investments
- In April 2020, private equity firm TPG acquired LifeStance for $1.2 billion in equity, joining existing investors Summit Partners and Silversmith Capital Partners.
- Post-IPO in 2021, private equity owners TPG, Summit Partners, and Silversmith Capital Partners collectively retained a significant ownership stake, approximately 64%-66% of the company.
Outbound Investments
- LifeStance's historical growth included nearly 100 acquisitions of behavioral health practices over the past six years (as of early 2024), completing its 50th acquisition in 2020.
- Following its 2021 IPO, the company shifted away from an aggressive merger and acquisition (M&A) strategy to focus on organic growth and optimizing its clinic footprint.
- The company anticipates a return to disciplined M&A in 2025 and 2026, targeting opportunities for geographic expansion and enhancing service offerings.
Capital Expenditures
- Year-to-date through Q3 2025, capital expenditures amounted to $25 million.
- Capital expenditures in the last 12 months (up to November 2025) were approximately $31.52 million.
- The primary focus of capital expenditures includes selective deployment for new centers to support clinician and market growth, as well as strategic investments in infrastructure, technology, and system upgrades to enhance operational efficiency, such as unifying electronic health records and developing digital tools.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to LFST. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for LifeStance Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 15.8% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 13.4% |
| FCF/Rev 3Y Avg | 12.1% |
Price Behavior
| Market Price | $7.13 | |
| Market Cap ($ Bil) | 2.8 | |
| First Trading Date | 06/10/2021 | |
| Distance from 52W High | -12.7% | |
| 50 Days | 200 Days | |
| DMA Price | $6.12 | $5.70 |
| DMA Trend | down | up |
| Distance from DMA | 16.5% | 25.1% |
| 3M | 1YR | |
| Volatility | 67.1% | 52.6% |
| Downside Capture | -58.90 | 88.48 |
| Upside Capture | 85.13 | 69.59 |
| Correlation (SPY) | 5.8% | 24.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.17 | 0.22 | 0.30 | 0.97 | 0.70 | 0.93 |
| Up Beta | 1.89 | 1.67 | 1.84 | 1.47 | 0.75 | 1.00 |
| Down Beta | 0.54 | 0.61 | 0.02 | 0.13 | 0.35 | 0.59 |
| Up Capture | 56% | 51% | 57% | 111% | 65% | 100% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 10 | 19 | 28 | 54 | 111 | 363 |
| Down Capture | -379% | -71% | -30% | 131% | 102% | 103% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 21 | 32 | 64 | 126 | 360 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullReturns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 0.6% | 1.0% | 3.7% |
| 8/7/2025 | 13.2% | 44.6% | 45.3% |
| 2/27/2025 | 0.6% | 1.8% | -13.4% |
| 11/7/2024 | -4.2% | -5.9% | -3.3% |
| 8/8/2024 | -5.6% | -1.5% | 17.5% |
| 5/9/2024 | -3.7% | 3.5% | -24.9% |
| 2/28/2024 | -4.1% | -16.9% | -29.2% |
| 11/8/2023 | -3.4% | 5.2% | 14.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 8 | 7 |
| # Negative | 9 | 7 | 8 |
| Median Positive | 2.9% | 5.9% | 17.5% |
| Median Negative | -5.1% | -16.9% | -23.1% |
| Max Positive | 17.3% | 44.6% | 45.3% |
| Max Negative | -46.5% | -38.8% | -29.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8072025 | 10-Q 6/30/2025 |
| 3312025 | 5072025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 2282024 | 10-K 12/31/2023 |
| 9302023 | 11082023 | 10-Q 9/30/2023 |
| 6302023 | 8092023 | 10-Q 6/30/2023 |
| 3312023 | 5102023 | 10-Q 3/31/2023 |
| 12312022 | 3092023 | 10-K 12/31/2022 |
| 9302022 | 11092022 | 10-Q 9/30/2022 |
| 6302022 | 8102022 | 10-Q 6/30/2022 |
| 3312022 | 5112022 | 10-Q 3/31/2022 |
| 12312021 | 3172022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Miller Lisa K | See Remarks | 11252025 | Sell | 6.43 | 57,240 | 368,053 | 1,680,108 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.